Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2014

View Archived Issues

Bayer HealthCare and University of Oxford collaborate on endometriosis and uterine fibroid research

MRC Technology and AstraZeneca renew collaboration to identify novel targets

Medicure acquires minority position in Apicore

Researchers present a novel insulin analogue with improved glycemic control

Japanese approval for Dovobet to treat psoriasis vulgaris

MRZ-9547 assessed in Parkinson's disease models, enters phase I in healthy subjects

Zalviso MAA submitted in Europe

Early clinical results presented for PEX-168

Lundbeck patents novel nAChR alpha7 PAMs

Merck KGaA prepares new BTK inhibitors

Novartis synthesizes novel pyridone derivatives for tuberculosis

New CDK8/CCNC inhibitors synthesized by Roche

Researchers at Roche and Genentech divulge novel RORC modulators for arthritis

Nexavar approved in Canada for differentiated thyroid cancer

Promising phase I data presented for a number of oncolytic immunotherapy candidates

Japan approves first all-oral interferon- and ribavirin-free HCV treatment

Endo and BioDelivery Sciences report data from phase III BEMA buprenorphine trial

Data safety monitoring recommends continuation of phase IIb brilacidin trial

BeiGene initiates phase I trial of PARP inhibitor BGB-290

Cardio3 BioSciences enrolls 120th patient in the phase III CHART-1 study

Celladon provides update on Mydicar development

Mekinist approved in E.U. for metastatic melanoma with a BRAF V600 mutation

Anoro Ellipta approved in Japan for COPD

FDA approves NovoSeven RT for Glanzmann's thrombasthenia

FDA breakthrough therapy designation granted to cell therapy for leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...